{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Napitane [A 75200, ABT 200] is a norepinephrine uptake inhibitor and α2 adrenoceptor antagonist. It was undergoing clinical trials with Abbott in the USA as a treatment for depression. However it was discontinued later. Napitane is a potent alpha 2-adrenoceptor antagonist (Ki = 1.2 nM) with modest norepinephrine uptake-blocking activity (IC50 = 841 nM).
Status:
Investigational
Source:
NCT01000493: Phase 2 Interventional Completed Post-Traumatic Stress Disorder
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Orvepitant is a novel generation brain penetrant, selective and potent, small molecule NK-1 receptor antagonist. Orvepitant’s (GW823296) mode of action and developability characteristics made it a suitable development candidate for the treatment of common anxiety disorders, posttraumatic stress disorder and major depressive disorder. It’s in phase II clinical trials as an effective inhibitor of itch-associated response.
Status:
Investigational
Source:
NCT03414034: Phase 2 Interventional Completed Metastatic Castration-Resistant Prostate Cancer
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
NMS-P937 is a selective PLK1 inhibitor. It was developed by Nerviano Medical Sciences and tested in phase I clinical trials.
Status:
Investigational
Source:
NCT04390295: Phase 3 Interventional Unknown status Type 2 Diabetes Mellitus
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. This drug successfully passed phase I clinical trials, however, information about further development is not available.
Status:
Investigational
Source:
NCT01740986: Phase 2 Interventional Completed Mild to Moderate Bronchial Asthma
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Masilukast (ZD 3523) is an antagonist of leukotriene D4 (LTD4). It opposes LTD4-induced bronchoconstriction. It was being developed for the treatment of asthma.
Status:
Investigational
Source:
USAN:ONVANSERTIB FUMARATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT00189735: Phase 2 Interventional Completed Kidney Transplantation
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Manitimus (FK778) is a synthetic malononitrilamide (MNA) that has been demonstrated to have both both immunosuppressive and anti-proliferative activities. The MNAs inhibit both T-cell and B-cell function by blocking de novo pyrimidine synthesis, through blockade of the pivotal mitochondrial enzyme dihyroorotic acid dehydrogenase, and the inhibition of tyrosine kinase activity. It directly reduced endothelial adhesion molecule up-regulation, inhibited lymphocyte activation, and attenuated lymphocyte-endothelium interactions, critical early steps in graft rejection. Manitimus has been demonstrated to prevent acute allograft rejection in multiple experimental transplant models in rodents, dogs and primates and to be effective in the rat model of chronic renal allograft rejection. It was in clinical studies for the treatment of transplant rejection. Manitimus development has been discontinued.
Class (Stereo):
CHEMICAL (UNKNOWN)
Tolafentrine is phosphodiesterase 3/4 (PDE3/4) inhibitor. Treatment of endothelial cells with tolafentrine significantly decreased asymmetrical dimethylarginine-induced apoptosis via a cAMP/PKA-dependent pathway by induction of dimethylarginine dimethylaminohydrolase 2 (DDAH2). Chronic nebulization of PDE3/4 inhibitor significantly attenuated monocrotaline-induced hemodynamic, gas exchange abnormalities, vascular remodeling, and right heart hypertrophy. When chronically nebulized from day 28 to 42 (12 daily aerosol maneuvers), after full establishment of severe pulmonary hypertension, tolafentrine reversed about 60% of all hemodynamic abnormalities in rats, right heart hypertrophy and monocrotaline-induced structural lung vascular changes, including the proportion of pulmonary artery muscularization. Tolafentrine was developed as therapeutic agent for the treatment of asthma. However, this development was discontinued.
Class (Stereo):
CHEMICAL (RACEMIC)
Pamatolol is a beta-Adrenergic receptor antagonist was studied as an Antiarrhythmic agent. The phase I clinical trial has shown that the drug was relatively cardioselective in man. Information about the further development of this drug is not available.
